Manatuck Hill Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Manatuck Hill Partners’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,480	Closed	-$472K	–	100
2019 Q2	$472K	Sell	9,480 -2,690	-22%	-$224K	0.22%	81
2019 Q1	$961K	Buy	+12,170	New	+$785K	0.46%	56
2017 Q2	–	Sell	-4,198	Closed	-$500K	–	97
2017 Q1	$500K	Hold	4,198	–	–	0.22%	67
2016 Q4	$592K	Buy	4,198 +1,358	+48%	+$150K	0.29%	59
2016 Q3	$286K	Sell	2,840 -585	-17%	-$47.2K	0.11%	79
2016 Q2	$244K	Buy	3,425 +334	+11%	+$31.2K	0.11%	72
2016 Q1	$285K	Buy	+3,091	New	+$274K	0.1%	74

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

DAM

Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return

Manatuck Hill Partners's IMDX Position: Q3 2019 in Review

Manatuck Hill Partners sold out of Insight Molecular Diagnostics (IMDX) in Q3 2019, closing a stake of 9,480 shares — an estimated $472K sold.

Manatuck Hill Partners first reported a position in IMDX in Q1 2016 and held it in 7 quarters. The position peaked at $961K in Q1 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q3 2019.

Manatuck Hill Partners reported no remaining Insight Molecular Diagnostics position as of Q3 2019 after selling out during the quarter.
Manatuck Hill Partners sold 9,480 Insight Molecular Diagnostics shares in Q3 2019, an estimated $472K.
Manatuck Hill Partners first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 7 quarters.
Manatuck Hill Partners's Insight Molecular Diagnostics position peaked at $961K in Q1 2019.
56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2019.

Based on Manatuck Hill Partners's 13F filing for Q3 2019, filed 14 Nov 2019.